Please login to the form below

Wilmington Healthcare launches new platform to map the formulary landscape

Healthcare intelligence provider Wilmington Healthcare has launched a new platform that enables pharma companies to develop a clear picture of formulary status across therapy areas and territories in the UK.

4 February 2021

Wilmington Healthcare launches new platform to map the formulary landscape

Healthcare intelligence provider Wilmington Healthcare has launched a new platform that enables pharma companies to develop a clear picture of formulary status across therapy areas and territories in the UK.

Known as InFormulary XD, the solution uses a unique blend of data and real-world evidence to provide an objective view of the status of a product by indication, on formularies and within guidelines.

Users can drill down into NHS localities within defined territories to gain a more detailed view of how their products are performing in primary and secondary care and better understand the challenges where formularies overlap.

The tool’s grading system also enables companies to clearly see where their brands sit on formularies and benchmark their performance against the competition using a wealth of data and insight.

In addition, the platform can be used to connect formulary information with other data sources, such as key stakeholder databases and NHS documents associated with product indication and target formularies.

Armed with data and insights from the platform, pharma can create compelling go-to-market plans to improve or maintain market position, monitor progress and keep abreast of formulary changes at a glance.

Gareth Thomas, Managing Director of Wilmington Healthcare, said: “The formulary landscape is not only multi-layered and complex, it is also changing quickly as the NHS adopts the integrated care models outlined in the Long-term Plan. This means that formulary data must be regularly reviewed and updated.

“Our new InFormulary XD enables customers to build and maintain a comprehensive view of a product’s formulary status in the UK in real-time and benchmark its performance against the competition. This level of insight, combined with related stakeholder data, gives companies a real competitive advantage in everything from strategic planning, budgeting and resourcing to customer targeting.”

Ends

Notes to Editors

For more information, please contact: Andrew Baud and Catherine McNulty, Tala, +44 (0) 20 3397 3383 or +44 (0) 7775 715775, Email: andrew.baud@teamtala.com /catherine.mcnulty@teamtala.com

4th February 2021

Share

Company Details

Wilmington Healthcare

01268 495600

Contact Website

Address:
Beechwood House
2-3 Commercial Way
Christy Close
Southfields
Basildon
SS15 6EF
United Kingdom

Latest content on this profile

Covid-19: how is it affecting prescribing patterns?
Oli Hudson, Content Director at Wilmington Healthcare, analyses prescribing data in three key disease areas
Wilmington Healthcare
Wilmington Healthcare launches new platform to map the formulary landscape
Healthcare intelligence provider Wilmington Healthcare has launched a new platform that enables pharma companies to develop a clear picture of formulary status across therapy areas and territories in the UK.
Wilmington Healthcare
Wilmington Healthcare appoints new Head of Digital

Wilmington Healthcare
How has the pandemic reshaped the NHS in 2020?
Oli Hudson, of Wilmington Healthcare, explores the major changes that have occurred across the NHS as key aspects of the Long Term Plan are rolled out at speed.
Wilmington Healthcare
Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset
Wilmington Healthcare
How can pharma align its brand strategy with the NHS Reset?
Oli Hudson, of Wilmington Healthcare, explores how pharma should respond to plans to ‘reboot’ the NHS during the covid recovery era
Wilmington Healthcare